Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composite for treating cerebrovascular diseases

A cerebrovascular disease and composition technology, applied in the field of pharmaceutical compositions for the treatment of cerebrovascular diseases and their preparation, can solve the problems of large dosage, high price, unfavorable use by patients and the like

Active Publication Date: 2010-07-07
杜守颖
View PDF0 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Western medicine mainly uses aspirin, nimodipine, citicoline and other drugs, which are not only prone to allergic reactions and drug resistance, but also have relatively toxic side effects
Commonly used drugs in TCM treatment mainly include Compound Musk Injection, Ginkgo Ketone Ester Dropping Pills, Angong Niuhuang Pills, Tianxintai Xueshuan Xinmaining Tablets, etc. Although they are safe to take and have no side effects, the purity of the active ingredients is not high. , the preparation process is original, the dosage is large, it is inconvenient for patients to take it, the price is expensive, and it is not conducive to the use of patients
Therefore, there is not yet a highly pure, safe and effective traditional Chinese medicine compound preparation for the treatment of acute cerebrovascular diseases.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composite for treating cerebrovascular diseases
  • Pharmaceutical composite for treating cerebrovascular diseases
  • Pharmaceutical composite for treating cerebrovascular diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0130] Embodiment 1: tablet

[0131] Musk 7.5kg Moxa slice 1kg

[0132] Turmeric volatile oil 0.05L Gardenia active components 2.4kg

[0133] Grinding and mixing the effective components of musk and gardenia to form a drug powder, and inclusion of moxa tablets and β-cyclodextrin at a ratio of 1:7 to make a cyclodextrin inclusion compound of moxa tablets; Mix the clathrate, and mix it with lactose in a ratio of 2:1, add polyvinylpyrrolidone K30 dry powder equivalent to 10% of the total weight of the powder, mix well, moisten the soft material with absolute ethanol, granulate with a 20-mesh sieve, spray Add the turmeric volatile oil dispersed with ethanol, place it at room temperature, evaporate the ethanol, sieve the 20-mesh sieve, press into tablets, and coat;

[0134] In the preparation method of above-mentioned tablet, turmeric volatile oil is made by following method:

[0135] Take turmeric, crush it into the size of bean grains, add 10 times the amount of water, extract b...

Embodiment 2

[0138] Embodiment 2: tablet

[0139] Musk 7.5kg borneol 1kg

[0140] Turmeric volatile oil 0.05L Gardenia active components 2.4kg

[0141] Grind and mix the effective components of musk, borneol, and gardenia to form a medicinal powder. Mix the medicinal powder and microcrystalline cellulose evenly in a ratio of 2:1, add polyvinylpyrrolidone K30 dry powder equivalent to 10% of the total weight of the medicinal powder, mix well, and dehydrated alcohol Wet the soft material, granulate with a 20-mesh sieve, spray into the turmeric volatile oil dispersed with ethanol, place at room temperature, evaporate the ethanol, granulate with a 20-mesh sieve, press into tablets, and coat;

[0142] In the preparation method of above-mentioned tablet, turmeric volatile oil is made by following method:

[0143] Take turmeric, crush it into the size of bean grains, add 10 times the amount of water, extract by steam distillation for 6 hours, separate and collect the volatile oil, and obtain the...

Embodiment 3

[0146] Embodiment 3: tablet

[0147] Musk 7.5kg Moxa slice 1kg

[0148] Turmeric volatile oil 0.05L Gardenia active components 2.4kg

[0149] The effective components of musk and gardenia are pulverized and mixed into a medicinal powder, and the moxa tablet and polyvinylpolypyrrolidone XL are ground and mixed at a ratio of 1:5 to make a physical mixture of moxa tablet polyvinylpolypyrrolidone; Pyrrolidone physical mixture is mixed, and mixed with microcrystalline cellulose or lactose at a ratio of 2:1, and polyvinylpyrrolidone K30 dry powder equivalent to 10% of the total weight of the drug powder is added, mixed, and anhydrous ethanol is used to wet the soft material, 20 mesh Sieve and granulate, spray turmeric volatile oil dispersed with ethanol, place at room temperature, evaporate ethanol, granulate with 20-mesh sieve, press into tablets, and coat;

[0150] In the preparation method of above-mentioned tablet, turmeric volatile oil is made by following method:

[0151] T...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a pharmaceutical composite, in particular to a pharmaceutical composite for treating cerebrovascular diseases and a preparation method thereof. The pharmaceutical composite is prepared from four active pharmaceutical ingredients of moschus, blumea camphor or borneol, turmeric essential oil and Cape jasmine fruit. The active ingredient of the Cape jasmine fruit in the pharmaceutical composite mainly comprises iridoid glycosides. Through pharmacological research, the result shows that the iridoid glycosides have extensive bioactivity and benefit cerebral nervous system and cardiovascular system. Through efficacy experiment, the result shows that the pharmaceutical composite has the obvious effects of alleviating the cerebral infarction of MCAT rat and improving the nervous syndrome.

Description

field of invention [0001] The invention relates to a pharmaceutical composition, in particular to a pharmaceutical composition for treating cerebrovascular diseases and a preparation method thereof. Background technique [0002] Acute cerebrovascular disease refers to a group of diseases with sudden onset of cerebral vascular circulation disorders. It can be caused by sudden thrombosis of cerebral blood vessels, cerebral embolism resulting in ischemic cerebral infarction, or cerebral hemorrhage caused by rupture of cerebral blood vessels, often accompanied by Nervous system symptoms, limb hemiplegia, aphasia, mental symptoms, dizziness, ataxia, coughing, coma or even death in severe cases, clinically also known as cerebrovascular accident, stroke or apoplexy. The onset of this disease is sudden, with many symptoms and rapid changes, often leaving sequelae. In recent years, the incidence rate has been increasing, and the age of onset is also tending to be younger. Therefore,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K36/9066A61K9/08A61K9/10A61K9/16A61K9/20A61K9/28A61K9/48A61P9/10A61P25/00A61K35/55A61K31/045
Inventor 杜守颖
Owner 杜守颖
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products